- Home
- ABSI vs RIGL Comparison
ABSI vs RIGL Comparison
Compare ABSI & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- RIGL
- Stock Information
- Founded
- ABSI 2011
- RIGL 1996
- Country
- ABSI United States
- RIGL United States
- Employees
- ABSI N/A
- RIGL N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- RIGL Health Care
- Exchange
- ABSI Nasdaq
- RIGL Nasdaq
- Market Cap
- ABSI 338.0M
- RIGL 335.5M
- IPO Year
- ABSI 2021
- RIGL 2000
- Fundamental
- Price
- ABSI $2.39
- RIGL $38.85
- Analyst Decision
- ABSI Strong Buy
- RIGL Buy
- Analyst Count
- ABSI 5
- RIGL 5
- Target Price
- ABSI $7.98
- RIGL $38.20
- AVG Volume (30 Days)
- ABSI 4.4M
- RIGL 995.6K
- Earning Date
- ABSI 08-12-2025
- RIGL 08-05-2025
- Dividend Yield
- ABSI N/A
- RIGL N/A
- EPS Growth
- ABSI N/A
- RIGL N/A
- EPS
- ABSI N/A
- RIGL 5.43
- Revenue
- ABSI $4,138,000.00
- RIGL $267,921,000.00
- Revenue This Year
- ABSI $44.71
- RIGL $59.93
- Revenue Next Year
- ABSI $374.26
- RIGL N/A
- P/E Ratio
- ABSI N/A
- RIGL $7.15
- Revenue Growth
- ABSI 27.32
- RIGL 105.62
- 52 Week Low
- ABSI $2.01
- RIGL $12.66
- 52 Week High
- ABSI $6.33
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- ABSI 33.33
- RIGL 68.57
- Support Level
- ABSI $2.50
- RIGL $39.00
- Resistance Level
- ABSI $2.73
- RIGL $42.08
- Average True Range (ATR)
- ABSI 0.18
- RIGL 2.32
- MACD
- ABSI -0.04
- RIGL -0.37
- Stochastic Oscillator
- ABSI 1.94
- RIGL 53.26
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.